Normally, for a patient with IgA Nephropathy, he or she will spend 5-20 years to develop into kidney failure. However, if she or he has a serious condition and left it uncontrolled, this period is likely to be shortened to 2-3 years, even shorter. In view of this, many patients may ask how to avoid IgA Nephropathy develop into Kidney failure effectively. Don’t be anxious, please read on and the answer is expected to be showed in the below content.
Firstly, as we all know that a well-planned and proper diet indeed plays a helpful role in slowing the progression of IgA Nephropathy and helping avoid kidney failure. However, though patients are all diagnosed with IgA Nephropathy, but the illness condition of each person varies from case to case. In view of this, if you want to get some personalized suggestions, please send your recent check report to email@example.com as soon as possible or chat with our online doctors for free help, we are here to help you.
Secondly, steroids or immunosuppressive medicines are also commonly used by IgA Nephropathy patients to slow its progression. There is no doubt that these medicines can eliminate the proteinuria and improve kidney function in a certain degree exactly. Unfortunately, only a few patients have good response to it and more patients don’t get the ideal therapeutic effect after taking these medicines, what is worse, even aggravate the illness condition.
Thirdly, is there a effective treatment to avoid IgA Nephropathy develop into kidney failure? Here, we would like to introduce the newest treatment for IgA nephropathy known as Immunotherapy which mainly aims at blocking further decline of kidney function, repairing the damaged kidney and restoring the disordered immune system by a series of steps, like immune diagnosis, immune clearance, immune blocking, immune tolerance, immune adjustment and immune protection.
Finally, do you want to know the detailed process of the above steps? If yes, please contact us immediately, we are looking forward to your consulting. Best wishes.